FOLD

NEUTRALM&A

Amicus Therapeutics, Inc.

2026-03-17

Price

$14.37

+0.00%

Score6.5Priority

Signals5/8 DNA2/13 Act · 1/4 Risk

SentimentNEUTRALScore: 8

Volume0.9xvs 20d avg

Analysis

FOLD's uniquely low annualized volatility of 1.9% and steady price action are the direct result of its pending $14.50 all-cash acquisition by BioMarin. The suite of technical signals (ALPHA_MALE, QUIET_STORM, PERFECT_STACK) perfectly captures this merger arbitrage dynamic as institutional buyers accumulate shares to capture the remaining spread. While the broader macro regime flashes CAUTION due to geopolitical risks, exceptionally low credit spreads (0.94%) provide high conviction that financing for the $4.8 billion deal remains secure and deal-break risk is minimal. With the FTC already granting early termination of the HSR waiting period, the stock is simply marking time until the expected Q2 2026 close.

Fired Signals

ALPHA MALEQUIET STORMGOLDEN CROSSBOLLINGER SQUEEZEPERFECT STACKSELLER FATIGUEBARGAIN HUNTERWEAK FINISH

Key Takeaways

Actionable Thesis: FOLD functions as a definitive merger arbitrage vehicle, offering a low-risk spread up to the $14.50 BioMarin buyout price.
Key Risk: The primary risk is a black-swan deal cancellation, though regulatory hurdles are already clearing following the FTC's early termination in February.
What to Watch: Monitor the final shareholder vote and any M&A financing updates from BioMarin ahead of the Q2 2026 closing window.

← Back to 2026-03-17 View Full FOLD History →Yahoo Finance &nearr;